Efficacy criteria and cholesterol targets for LDL apheresis.

[1]  S. Humphries,et al.  Familial hypercholesterolaemia: identification and management , 2017, Pharmaceutical Journal.

[2]  G. Utermann,et al.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events , 2009, Nature Clinical Practice Cardiovascular Medicine.

[3]  D. Rader,et al.  Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. , 2008, The American journal of cardiology.

[4]  B. Kleinman,et al.  Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. , 2008, The American journal of cardiology.

[5]  J. Schlienger,et al.  Low‐density Lipoprotein Apheresis in Children With Familial Hypercholesterolemia: Follow‐up to 21 Years , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  G. Thompson.  Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.

[7]  E. Sijbrands,et al.  PO23-746 ISIS 301012, AN ANTISENSE INHIBITOR OF APO B, PRODUCES SIGNIFICANT ADDITIONAL REDUCTION OF LDL-C & APOB IN HYPERCHOLESTEROLEMIC SUBJECTS ON STATINS NOT MEETING TARGET , 2007 .

[8]  Richard E Gregg,et al.  Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[9]  F. Civeira,et al.  Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. , 2004, Atherosclerosis.

[10]  O. Descamps,et al.  Impact of genetic defects on coronary atherosclerosis in patients suspected of having familial hypercholesterolaemia , 2003, European journal of clinical investigation.

[11]  V. Armstrong,et al.  First Steps Toward the Establishment of a German Low‐Density Lipoprotein‐Apheresis Registry: Recommendations for the Indication and for Quality Management , 2002 .

[12]  D. Gaudet,et al.  Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia , 2002, Circulation.

[13]  W. März,et al.  The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations , 2001, Clinical chemistry and laboratory medicine.

[14]  K. Parhofer,et al.  Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. , 2000, Journal of lipid research.

[15]  M. V. van’t Hof,et al.  The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. , 2000, Atherosclerosis.

[16]  P. Nihoyannopoulos,et al.  Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia , 1998, Heart.

[17]  Clare,et al.  Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. , 1997, Journal of lipid research.

[18]  A. Soutar,et al.  Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. , 1996, Journal of lipid research.

[19]  R. Naoumova,et al.  The Extracranial Carotid Artery in Familial Hypercholesterolemia: Relationship of Intimal-Medial Thickness and Plaque Morphology with Plasma Lipids and Coronary Heart Disease , 1996, Journal of cardiovascular risk.

[20]  R. Prescott,et al.  Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis , 1995, The Lancet.

[21]  T. Risler,et al.  Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. , 1994, Journal of lipid research.

[22]  J. Hoeg,et al.  Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  V. Armstrong,et al.  No evidence for feedback inhibition of hepatic apolipoprotein B (apo B) production after extracorporeal low density lipoprotein precipitation as determined by [I‐13C]leucine infusion in normal volunteers , 1993, European journal of clinical investigation.

[24]  A. Marais,et al.  Fatal outcome of homozygous familial hypercholesterolaemia in a black patient. A case report. , 1990, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[25]  S. Grundy,et al.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983. , 1983, Atherosclerosis. Supplements.

[26]  G. Thompson.  PLASMA EXCHANGE FOR HYPERCHOLESTEROLAEMIA , 1981, The Lancet.

[27]  T. Spinks,et al.  Non-stedy-state studies of low-density-liproprotein turnover in familial hypercholesterolaemia. , 1977, Clinical science and molecular medicine.

[28]  Paulsen Ca.  Letter: Cyproterone acetate. , 1976 .

[29]  R. Weinstein,et al.  Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis , 2010, Journal of clinical apheresis.

[30]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.